医学
免疫疗法
肺癌
肿瘤科
癌症免疫疗法
生物标志物
生物标志物发现
PD-L1
癌症
内科学
重症监护医学
蛋白质组学
生物化学
基因
化学
作者
Deniz Can Guven,Taha Koray Sahin,Omer Dizdar,Saadettin Kilickap
出处
期刊:Biomarkers in Medicine
[Future Medicine]
日期:2020-10-01
卷期号:14 (14): 1383-1392
被引量:14
标识
DOI:10.2217/bmm-2020-0310
摘要
In recent years, immune checkpoint inhibitors have rapidly changed treatment paradigms and have been pivotal for the treatment of advanced NSCLC patients. However, many patients don't respond to immunotherapy, and toxicities are a concern. Mounting evidence suggests that PD-L1 expression and tumor mutational burden are useful biomarkers in NSCLC and widely used in clinical practice. Given various limitations of PD-L1 and tumor mutational burden, many candidate biomarkers have emerged. From these biomarkers, peripheral blood-based biomarkers are promising options for the prediction of immunotherapy efficacy with ease of access, repeatability and low cost. This review provides an overview of recent developments on the biomarkers in immunotherapy efficacy together with comments on future perspectives.
科研通智能强力驱动
Strongly Powered by AbleSci AI